Key facts
- This page summarizes David Daly's Form 4 filing for Singular Genomics Systems, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Mar 2022, 18:03.
David Daly - 04 Mar 2022 Form 4 Insider Report for Singular Genomics Systems, Inc.
- Reporting relationship
- President and Chief Operating
- Issuer ticker
- N/A
- Reported as of
- 04 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2022, 18:03:38 UTC
- Prior SEC filing
- 12 Nov 2021
- Next SEC filing
- 14 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dalen Meeter, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
David Daly filed Form 4 for Singular Genomics Systems, Inc. on 08 Mar 2022.
Change
- Previous filing in this sequence was filed on 12 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OMIC
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- $7.50
- Footnotes
- F1
OMIC
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +125,000
- Change %
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- $7.50
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option shares vest and become exercisable in 48 equal monthly installments measured from March 4, 2022.
Footnote F2
Subject to the achievement of certain performance targets by December 31, 2022, 25% of the option shares will vest and become exercisable on March 4, 2023, and the remaining option shares will vest and become exercisable in 36 equal monthly installments thereafter as the Reporting Person continues to provide services to the Issuer.